Osborne Clarke has just advised global healthcare company Grifols on its 60% acquisition of Progenika, a biotechnology firm for €37 million.

This is the third deal Osborne Clarke has closed for Grifols in the past 6 months, having previously advised on the buy-back of 4.4 million B shares from Cerberus and the refinancing of Scranton enterprises, a major shareholder of Grifols.

Tomás Dagá, Osborne Clarke’s Barcelona-based Chairman, led on all 3 deals.

http://www.osborneclarke.co.uk/media/sectors/digital-business/2013/osborne-clarke-advises-grifols-on-its-acquisition-of-progenika.aspx